Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease

European Heart Journal

Volumn 31, Issue 21, 2010, Pages 2575-2576

  Van De Werf, Frans ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; E 5555; PROTEINASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR STIMULATING AGENT; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QT PROLONGATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMINES; MALE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1;

EID: 78149336649     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq283     Document Type: Note

References (4)

1. Fox KAA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, Buysschaert I, Lambrechts D, Van de Werf F. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study). Eur Heart J 2010; doi:10.1093/eurheartj/ehq326.
2. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-928.
3. Goto S, OgawaH, Takeuchi M, Flather MD, Bhatt DL, on behalf ofthe J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010;31:2601-2613. First published on 30 August 2010. doi:10.1093/eurheartj/ ehq320.
4. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2009; 17:156-164.